Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171641
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Taberna, Miren | - |
dc.contributor.author | Torres, Montserrat | - |
dc.contributor.author | Alejo, Maria | - |
dc.contributor.author | Mena Cervigón, Marisa | - |
dc.contributor.author | Tous, Sara | - |
dc.contributor.author | Marquez, Sandra | - |
dc.contributor.author | Pavón Ribas, Miquel Àngel | - |
dc.contributor.author | León, Xavier | - |
dc.contributor.author | Garcia, Jacinto | - |
dc.contributor.author | Guix, Marta | - |
dc.contributor.author | Hijano, Rafael | - |
dc.contributor.author | Bonfill, Teresa | - |
dc.contributor.author | Aguilà, Anton | - |
dc.contributor.author | Lozano, Alicia | - |
dc.contributor.author | Mesía Nin, Ricard | - |
dc.contributor.author | Alemany i Vilches, Laia | - |
dc.contributor.author | Bravo, Ignacio G. | - |
dc.date.accessioned | 2020-11-02T14:14:56Z | - |
dc.date.available | 2020-11-02T14:14:56Z | - |
dc.date.issued | 2018-12-11 | - |
dc.identifier.uri | http://hdl.handle.net/2445/171641 | - |
dc.description.abstract | Background: Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on de-escalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. Our aim was to evaluate viral HPV16-E5 oncogene expression as well as EGFR and phosphorylated-EGFR (pEGFR), protein levels as biomarkers for clinical outcome in a retrospective cohort of OPC patients. Methods: Formalin-fixed-paraffin-embedded OPCs were collected from 1990 to 2013. OPC samples containing HPV-DNA were subject to viral E6* I mRNA detection and p16(INK4a) immunohistochemistry (IHC). HPV16-positive cases were evaluated for HPV16-E5 (RT-PCR) and EGFR/pEGFR (IHC). A stratified and matched random sample of HPV-negative samples was used as control and evaluated for EGFR/pEGFR. Overall survival (OS) and disease free survival (DFS) estimates were assessed for locally advanced OPC patients (stage III, IVa, b 7th edition). Results: Among 788 OPC patient samples, 53 were double positive for HPV16-DNA/p(16INK4a). HPV16-E5 expression was found in 41 of 53 samples (77.4%). EGFR expression was observed in 37.7 vs 70.8% of HPV16-positive vs HPV-negative samples, respectively; (adjusted OR = 0.15) 5% CI = 0.04-0.56]). Expression of pEGFR followed an inverse pattern with 39.6 and 24.9% detection in HPV16-positive and HPV-negative samples; (adjusted OR = 1.58 [95% CI = 0.48-5.17]). Within HPV16-positive cases, no association between HPV16-E5/EGFR nor pEGFR was observed. With a median follow-up of 39.36 months (min = 0.03 - max = 272.07), the combination of HPV status and EGFR or pEGFR expression were predictors of better OS (p < 0.001, for both) and DFS (p < 0.001 for EGFR and p = 0.003 for pEGFR). Conclusions: HPV16-E5 is highly expressed on HPV16-positive OPCs. Interestingly, HPV16-positive cases expressed significantly more pEGFR while HPV-negative cases expressed more EGFR. The combinations of HPV status and EGFR or pEGFR may be useful biomarkers for evaluating prognosis outcome in OPC patients. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media S. A. | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2018.00589 | - |
dc.relation.ispartof | Frontiers in Oncology, 2018, vol. 8 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2018.00589 | - |
dc.rights | cc by (c) Taberna et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Papil·lomavirus | - |
dc.subject.classification | Càncer | - |
dc.subject.other | Papillomaviruses | - |
dc.subject.other | Cancer | - |
dc.title | The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-10-26T09:28:28Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30619735 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
TabernaM.pdf | 2.49 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License